Becotatug vedotin: all 51 studies that test it

Page 1 of 1. Open to participants first (44), then studies with results posted, then the rest; newest registration first within each.

• Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later SettingRecruitingNCT07892833Phase 2
• Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard TherapyRecruitingNCT07892573Not applicable
• Vedotin for Injection in Second-line or Later Treatment of Advanced Biliary Tract CancerEnrolling by invitationNCT07890311Phase 2
• Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal CancerRecruitingNCT07884188Phase 2
• Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLCNot yet recruitingNCT07882940Phase 2
• Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLCRecruitingNCT07874581Not applicable
• ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCCNot yet recruitingNCT07844551Phase 2
• Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingNCT07825753Phase 2
• Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.RecruitingNCT07781358Phase 2
• Neoadjuvant Pucotenlimab and Becotatug Vedotin for Locally Advanced Penile CancerNot yet recruitingNCT07767266Phase 2
• Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell CarcinomaNot yet recruitingNCT07766889Phase 2
• Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-PositiveRecruitingNCT07712029Phase 2
• A Prospective, Exploratory Study of Becotatug Vedotin Plus Putlimab for Neoadjuvant Therapy and Adjuvant Radiotherapy in Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07707167Phase 2
• Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase IINot yet recruitingNCT07686926Phase 2
• MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07677475Phase 2
• Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell CarcinomaRecruitingNCT07665190Phase 2
• Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase IINot yet recruitingNCT07649980Phase 2
• Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung CancerNot yet recruitingNCT07627321Phase 2
• Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR MutationsNot yet recruitingNCT07598318Phase 2/3
• Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II StudyNot yet recruitingNCT07589049Phase 2
• Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell CarcinomaRecruitingNCT07586124Phase 2
• Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid TumorsRecruitingNCT07584499Phase 1
• ADC and SBRT for Recurrent/Metastatic Salivary Gland CarcinomaNot yet recruitingNCT07579598Phase 2
• Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal CarcinomaNot yet recruitingNCT07555860Phase 2
• Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)Not yet recruitingNCT07545083Phase 2
• Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular CarcinomaRecruitingNCT07536789Phase 2
• Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2Not yet recruitingNCT07531979Phase 2
• Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT07524413Phase 3
• A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic CarcinomaRecruitingNCT07522879Phase 2
• EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile CancerRecruitingNCT07518979Phase 2
• Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With ImmunotherapyRecruitingNCT07496190Phase 2
• Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal CancerNot yet recruitingNCT07490119Phase 2
• Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With OligometastasesRecruitingNCT07481799Phase 3
• Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPCRecruitingNCT07459296Phase 3
• Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell CarcinomaNot yet recruitingNCT07394244Phase 2
• MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical TrialNot yet recruitingNCT07381699Phase 2
• A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell CarcinomaRecruitingNCT07381075Phase 2
• MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPCRecruitingNCT07331428Phase 2
• Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal CarcinomaNot yet recruitingNCT07303283Phase 2
• MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell CarcinomaRecruitingNCT07054307Phase 1
• A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaRecruitingNCT06976190Phase 3
• A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06530914Phase 2
• A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHNRecruitingNCT05751512Phase 3
• A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid TumorsRecruitingNCT05688605Phase 1/2
• Pembrolizumab + MRGOO3 as Neoadjuvant in NPCActive, not recruitingNCT07267338Phase 2
• A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.TerminatedNCT05188209Phase 2
• A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05126719Phase 2
• A Study of MRG003 in Patients With Advanced Solid TumorsCompletedNCT04868344Phase 1
• A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and NeckCompletedNCT04868162Phase 2
• A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract CancerCompletedNCT04838964Phase 2
• A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung CancerCompletedNCT04838548Phase 2

← Becotatug vedotin overview